Interaction initiatives between regulatory, health technology assessment and coverage bodies, and industry.
about
A Time-Trend Economic Analysis of Cancer Drug Trials.Integrated Simulation Framework for Toxicity, Dose Intensity, Disease Progression, and Cost Effectiveness for Castration-Resistant Prostate Cancer Treatment With EribulinHarmonization of reimbursement and regulatory approval processes: a systematic review of international experiences.Disease Progression Modeling: Key Concepts and Recent DevelopmentsHealth technology assessment of medicines in Greece: pharmaceutical industry executives' views.Incentivizing research into the effectiveness of medical devices.
P2860
Interaction initiatives between regulatory, health technology assessment and coverage bodies, and industry.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Interaction initiatives betwee ...... coverage bodies, and industry.
@en
Interaction initiatives betwee ...... coverage bodies, and industry.
@nl
type
label
Interaction initiatives betwee ...... coverage bodies, and industry.
@en
Interaction initiatives betwee ...... coverage bodies, and industry.
@nl
prefLabel
Interaction initiatives betwee ...... coverage bodies, and industry.
@en
Interaction initiatives betwee ...... coverage bodies, and industry.
@nl
P2093
P2860
P1476
Interaction initiatives betwee ...... coverage bodies, and industry.
@en
P2093
Berit Mørland
Chris Henshall
Franz Pichler
Katrine Frønsdal
Logan Mardhani-Bayne
Marianne Klemp
P2860
P304
P356
10.1017/S0266462312000591
P577
2012-10-01T00:00:00Z